KRAS and lung carcinoma: Although the mutation rate of KRAS G12C is less than 5% in Chinese lung cancer population while that in PDAC is less than 1% 140, it still brings promising treatment efficacy to the patients, which seems to open a new pattern of clinical research on KRAS mutated tumors.